Individualized Molecular Analyses Guide Efforts (IMAGE): A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer

Clinical Cancer Research

Volumn 23, Issue 2, 2017, Pages 379-386

  Parsons, Heather A ^a,c   Beaver, Julia A ^a   Cimino Mathews, Ashley ^a   Ali, Siraj M ^b   Axilbund, Jennifer ^a   Chu, David ^a   Connolly, Roisin M ^a   Cochran, Rory L ^a   Croessmann, Sarah ^a   Clark, Travis A ^b   Gocke, Christopher D ^a   Jeter, Stacie C ^a   Kennedy, Mark R ^b   Lauring, Josh ^a   Lee, Justin ^a   Lipson, Doron ^b   Miller, Vincent A ^b   Otto, Geoff A ^b   Rosner, Gary L ^a   Ross, Jeffrey S ^b   Slater, Shannon ^a   Stephens, Philip J ^b   Vandenberg, Dustin A ^a   Wolff, Antonio C ^a   Young, Lauren E ^b   Zabransky, Daniel J ^a   Zhang, Zhe ^a   Zorzi, Jane ^a   Stearns, Vered ^a   Park, Ben H ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b FOUNDATION MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CELL FREE CIRCULATING PLASMA TUMORDNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ANALYSIS; ANALYTIC METHOD; ARTICLE; BAP1 GENE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEASIBILITY STUDY; FEMALE; GENE; GENE FREQUENCY; GENE LOSS; GENOMICS; HUMAN; HUMAN TISSUE; INDIVIDUALIZED MOLECULAR ANALYSIS GUIDE EFFORT; METASTATIC TRIPLE NEGATIVE BREAST CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; OFF LABEL DRUG USE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SOMATIC MUTATION; TISSUE ANALYSIS; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; BIOPSY; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; DRUG THERAPY; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; DNA, NEOPLASM; DRUG THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PRECISION MEDICINE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85011003350     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1543     Document Type: Article

References (32)

1. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-40.
2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
3. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 2015;33:2753-62.
4. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 2015;6:8760.
5. Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, et al. Early and multiple origins of metastatic lineages within primary tumors. Proc Natl Acad Sci U S A 2016;113:2140-5.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multi-region sequencing. N Engl J Med 2012;366:883-92.
7. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 2016;22:369-78.
8. Diaz LAJr, Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
9. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.
10. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
11. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014;20:2643-50.
12. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
13. Chu D, Paoletti C, Gersch C, VanDenBerg D, Zabransky D, Cochran R, et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin Cancer Res 2016;22:993-9.
14. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54.
15. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
16. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90.
17. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
18. Stearns V, Park BH. Gene mutation profiling of breast cancers for clinical decision making: drivers and passengers in the cart before the horse. JAMA Oncol 2015;1:569-70.
19. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-12.
20. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-44.
21. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-37.
22. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446-51.
23. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
24. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014;20:1757-67.
25. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016 Jun 06. [Epub ahead of print].
26. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 2016;7:11579.
27. Bartnik NJ, Roberts JS, Gornick MC, Le LQ, Chinnaiyan AM. Are oncologists using genome sequencing results to inform patient care? J Clin Oncol 2015;suppl; abstr e12525.
28. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014;15:267-74.
29. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res 2014;16:210.
30. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 2016;6:147-53.
31. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015;7:302ra133.
32. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715-22.